INCR Stock Analysis: Buy, Sell, or Hold?

INCR - Intercure Ltd. Ordinary Shares

Pharmaceutical Preparations
$0.96
-0.01 (-0.52%) â–ŧ
5d: -0.82%
30d: +0.53%
90d: +16.45%
WAIT
LOW Confidence
Analysis Updated: Aug 10, 2026 12:00 AM ET
Earnings: Jul 30, 2026 0d

Get Alerted When INCR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
â„šī¸ NEUTRAL: INCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
See Forward Earnings Fair Value & Price Prediction →

In-depth Analysis How we analyze

Valuation Analysis: INCR is currently trading at $0.95, which is considered fair relative to its 30-day fair value range of $0.92 to $0.98.

Technical Outlook: Technically, INCR is in a strong uptrend. Immediate support is located at $0.88, while resistance sits at $1.00.

Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.56 (+3395.8%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $0.92 - $0.98
Company Quality Score 50/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 74.7%

All Signals

  • NEUTRAL: Price in fair range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 3395.8% below Wall St target ($33.56)
  • WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $0.92 - $0.98
Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $0.88
Resistance Level $1.00
Current Trend Strong Uptrend
Technical data as of Aug 10, 2026

Fundamental Context

Forward P/E (Next Year Est.) 6.18
Wall Street Target $33.56 (+3395.8%)
Revenue Growth (YoY) 23.9%
Earnings Growth (YoY) -84.7%
Profit Margin -13.2%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 11, 2026 10:12 AM ET
Data refreshes hourly during market hours. Next update: 11:12 AM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for INCR.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences Iâ€Ļ
STRONG BUY
25 analysts
$213 60 BUY
BCRX
BioCryst Pharmaceuticalsâ€Ļ
STRONG BUY
12 analysts
$21 54 HOLD
ZTS
Zoetis Inc
BUY
20 analysts
$108 46 HOLD
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$107 47 HOLD
UTHR
United Therapeutics Corpâ€Ļ
STRONG BUY
15 analysts
$658 47 HOLD

More Analysis for INCR

INCR Technical Chart INCR Price Prediction INCR Earnings Date INCR Investment Advisor INCR Fair Price Analyzer INCR Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals